Significant progress in its clinical-development programs – and a chunky opt-in payment from a major international partner – won’t affect BioSpecifics Technologies Corp.’s financial fortunes until the third quarter, but…
A high-flying international performance by its flagship product Xiaflex marked a big year for Lynbrook pharma firm BioSpecifics Technologies Corp. The biopharmaceutical company reported its fourth-quarter and full-year 2015 financials…
By GREGORY ZELLER // “Innovative” is often associated with “new,” but when it comes to Long Island’s innovation economy, the region’s oldest biopharmaceutical company is leading the pack. With a…